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Abstract
Objective: Cervical intraepithelial neoplasia grades 2-3 (CIN2-3) are usually treated by cone excision, although only 30%
progress to cancer and 6–50% regress spontaneously. The aim of this study was to examine the influence of clinical factors
like smoking habits, number of lifetime sexual partners, age at first sexual intercourse, sexual activity span and hormonal
versus non-hormonal contraception type on the regression rate of CIN2-3.
Methods: In this prospective population-based cohort study 170 women aged 25–40 with abnormal cytology and
colposcopy-directed biopsies showing first time onset CIN2-3 were consecutively included. The interval between biopsy and
cone excision was standardized to minimum 12 weeks. Regression was defined as #CIN1 in the cone biopsy.
Results: The regression rate was 22%. Consistent condom use, defined as those women whose partners used condoms for
all instances of sexual intercourse, was infrequent (n = 20, 12%). In univariate analysis consistent condom use, hormonal
contraception and age at first sexual intercourse significantly predicted regression. In a multivariate analysis only consistent
condom use remained as an independent predictor of regression (regression rate 55%, p = 0.001, hazard ratio = 4.4).
Conclusion: Consistent condom use between punch biopsy and cone excision in first-time onset CIN2-3 patients
significantly increases the regression rate.
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Introduction
Human papillomavirus (HPV) is the major cause of cervical
intraepithelial neoplasia (CIN) [1]. CIN lesions are dynamic and
can persist or progress to invasive cancer [2], while 6–50% of all
CIN2-3 lesions regress spontaneously [3–5]. When left untreated,
about 31% of CIN3s will progress into invasive squamous
carcinoma (often over many years), compared to 0.7% of CIN3s
in conventionally treated women [6].
Standard treatment of CIN2-3 is cone excision, an invasive
procedure with potential complications [7]. Cervical insufficiency
is the most serious late-complication potentially leading to late
abortion or preterm delivery [8,9]. Since the large majority of
patients treated with cone excision are fertile women, the risk of
cervical insufficiency is a major concern [10].
The natural history of CIN-lesions may be influenced by the
HPV genotypes, the individual general and local immune response
and epithelial factors. Sexual behaviour, parity, contraceptives,
smoking habits and genetics are widely reported risk factors for
CIN development [5,11–17], but only a few studies have
examined the influence of these clinical factors on regression of
already established CIN lesion [5,18,19].
In order to evaluate the results from these hypothesis-generating
studies, we performed a prospective validation study investigating
the influence of hormonal contraception, number of lifetime
sexual partners, age at first sexual intercourse, smoking habits,
CIN-grade 2 or 23, age at diagnosis, biopsy–cone interval, parity
and family history of CIN or cervical cancer on the regression rate
in women with histological proven first-time onset CIN2-3. As
Hogewoning et al. reported that condom use promotes regression
of CIN2-3 and clearance of HPV in a prospective randomized
trial, special attention was given to validate the effect of condom
use on the regression rate [18].
It has previously been shown that an interval less than 9 weeks is
associated with a low regression rate of 5%. The regression rate
was extensively higher (38%), when intervals exceeded 9 weeks
[20]. Hogewoning et al also showed that the longer the interval,
the higher the regression rate [18]. Therefore, the interval between
biopsy and cone excision was limited to 12 weeks and more in the
current study.
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Materials and Methods
The study was approved by the Norwegian Regional Ethical
committee (# 303.06), the Social and Health Department (#07/
3300) and the Norwegian Social Science Data Service (#17185).
All patients gave written informed consent. The age was limited to
,41 years as the Ethics Committee regarded the risk of developing
micro invasive carcinoma in patients more than 40 years as too
high.
Gynecologic Methods
Women aged 25–40 years, who were referred to the gynecology
outpatient clinic, Stavanger University Hospital, between January
2007 and December 2008, for further diagnostic evaluation of
a population screening detected atypical cytological cervical
smear, were asked to participate. Atypical cytology was defined
according to the national Norwegian guidelines as: 1. LSIL + high-
risk (hr)-HPV; 2. ASCUS + hr-HPV; 3. Recurrences of two hr-
HPV positive cervical smears within six months; 4. ASC-H or 5.
HSIL.
Of the 254 initially included patients, 84 patients were excluded
due to normal or CIN1 histology in the biopsy, pregnancy,
significant comorbidity defined as diseases affecting the immune
system or need of treatment with immunosuppressive drugs,
previous treatment for CIN and biopsy-cone excision intervals
shorter than 80 days (Figure 1).
As part of the standard follow-up at the gynecology outpatient
clinic, Stavanger University Hospital, the patients came for
colposcopy, biopsy and endocervical curettage followed by cone
excision, if biopsy revealed CIN2 or CIN3. An additional visit 7–9
weeks after biopsy was part of the study protocol, due to the
slightly longer interval between biopsy and cone excision. At this
visit colposcopy was performed to detect eventually fast developing
premalignant mucosal changes.
Follow-up consisted of at least 3 visits to the gynecology
outpatient clinic as follows:
At the 1st visit, clinical data including sexual history, contra-
ception type, smoking habits, parity and family history of cervical
dysplasia or cancer were registered. The patients were asked to
continue their actual contraception. Colposcopy was performed
prior to punch biopsies and endocervical curettage.
At the 2nd visit (week 7–9) a second colposcopy was performed.
At the 3rd visit (between 12 and 24 weeks) information about
eventual changes of contraception type, including condom use was
collected. Consistent condom use was defined as those women,
whose partners used condoms for all instances of sexual in-
tercourse (in contrast to inconsistent condom use). Finally, after
a third colposcopy, a cone excision of the abnormal area was
performed using Loop Electrosurgical Excision Procedure.
Colposcopy at punch biopsy and cone excision is standard in
our hospital, and all colposcopy findings were documented.
Biopsy–cone excision intervals exceeding 16 weeks were patient
Figure 1. Inclusion and exclusion criteria. Norwegian guidelines for histological examination of atypical cytology were followed: 1. Low grade
Squamous Intraepithelial Lesion (LSIL) + high-risk Human Papillomavirus (hr-HPV) or 2. Atypical Squamous Cells of Undetermined Significance
(ASCUS) + hr-HPV or 3. Recurrences of hr-HPV positive cervical smears or 4. Atypical Squamous Cells, cannot rule out a High Grade lesion (ASC-H) or 5.
High Grade Squamous Intrepithelial Lesion (HSIL). AIS denotes Adenocarcinoma in situ and Bx Biopsy.
doi:10.1371/journal.pone.0045114.g001
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related. All patients were treated according to Norwegian
guidelines.
Pathology
Punch biopsies and cone biopsy material were fixed in 4%
buffered formaldehyde (24–48 hours) at ,20uC and embedded in
56uC paraffin. Eosin staining was performed prior to embedding
of the biopsies, to allow macroscopic identification of the
epithelium and reduce tangential cutting. Standard Hematoxylin
Erythrosin Saffran sections were used for histopathological
evaluation. As the diagnosis of CIN-1, 2 and 3, metaplasia or no
abnormalities is essential in the assessment of regression, all
histological sections of the 170 biopsies and 170 cone biopsies were
independently reviewed by two experienced pathologists (EG, JB).
They were blinded for patient data and each other`s diagnosis, and
used p16 and Ki67 in their review to support their diagnoses in all
cases. Regression was defined as a CIN2–3 in the cervical biopsy
and CIN1 or less in the subsequent cone biopsy.
Statistical Analysis
SPSS, version 18 (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Power calculation was based on a 25%
difference between the current percentage regression probability
and the expected regression probability. To obtain 90% power to
detect this difference, assuming a type one error of 5%, 46 patients
are needed. A drop-out rate of 30% due to histology #CIN1 and
other exclusion criteria were taken into account.
Data are presented as median with range unless otherwise
stated. The Kolmogorov-Smirnov test and visual inspection of
plots were used to test for normal distribution. Comparisons of
continuous variables were performed by 2-sided t-test or Mann-
Whitney U-test, as appropriate. Comparisons of categorical
variables were done using Chi-square. A multivariate binary
logistic regression model and Cox regression model was applied to
assess the influence of clinical variables as predictors for regression.
Probabilities of 0.05 were considered as statistically significant.
Results
The study population consisted of 170 women with a first-time
onset of atypical cytological smear and histologically proven
CIN2-3. No patient was lost to follow-up.
Basic and clinical characteristics of the study population are
shown in table 1. Median age was 30.8 (25–41) years and the
median biopsy-cone excision interval was 113 (84–171) days (7
cases had.140 days follow-up). The regression rate was 22% (38/
170). There were 39 CIN2 and 131 CIN3 lesions with regression
rates of 31% and 20%, respectively (p = 0.19). Age #15 years at
first sexual intercourse was associated with a significantly lower
regression rate (11%) compared to the group with a sexual debut
after the age of 15 (26%, p = 0.04). Neither smoking, the number
of lifetime sexual partners, nor the sexual activity span ( = interval
between first sexual intercourse and age at study inclusion) differed
significantly between the regression versus the non-regression
group. 58% of the study population had given birth at the median
age of 24 years. With nulliparous versus primiparous or
multiparous, neither the number of children nor the maternal
ages at first delivery were significantly correlated to the probability
of regression (Table 1).
Contraception used during the study was divided into a non-
hormonal group (20 consistent condom, 16 non-consistent
condom, 1 pessary, 2 non-hormonal IUD, 52 none contraceptives)
and a hormonal group (44 oral contraceptives, 27 hormonal IUD,
5 vaginal contraceptive ring, 2 contraceptive patch, 1 Depot
Medroxyprogesterone Acetate injection). Only 20 of 170 patients
(12%) reported consistent condom use. Clinicopathological
features between the 20 consistent condom users and other
patients did not differ significantly. Consistent condom use was
associated with a significantly higher regression rate of 55%
(hazard ratio 4.4) compared to patients using other types of
contraception or non-consistent condom use (18%, p = 0.001).
Inconsistent condom use did not significantly increase the
regression rate (Table 1).
The non-hormonal contraception group had a regression rate of
29%, which was significantly higher than in the hormonal
contraception group, 15% (p = 0.04). However, after adjusting
for consistent condom use, the difference lost its significance.
In a univariate analysis consistent condom use (p,0.001), use of
non-hormonal contraceptives (p = 0.04) and age at first sexual
intercourse .15 years (p = 0.04) were significantly associated with
regression. In a multivariate logistic regression model only
consistent condom use remained as an independent predictor of
regression.
Finally, a Cox regression analysis using the biopsy-cone interval
as the independent variable, revealed condom use as the only
independent regression predictor.
Discussion
We evaluated the influence of different clinicopathological
factors on regression of CIN2-3 in 170 patients. The overall
regression rate was 22%, which is in line with previously reported
regression rates of 5–50% [3,4,5]. Consistent condom use during
the study period was associated with a significantly increased
regression rate (55%), but inconsistent condom use was not. None
of the other clinical factors added into multivariate analyses
significantly predicted regression (Table 1).
Smoking, hormonal birth control and sexual behaviour as the
number of lifetime sexual partners, the age at first sexual
intercourse and the sexual activity span are considered risk factors
for the development of CIN. However, only few studies have
examined the influence of these factors on regression in patients
with established CIN [5,21], and none of them have evaluated the
effect of condom use on regression. In agreement with these two
studies, the current study confirmed that none of the examined
clinical factors are independent predictors of CIN regression.
Hogewoning et al reported an increased chance of CIN2-3
regression in patients using condoms with a hazard ratio of 3.1
compared to non-condom users. The current study is not
a hypothesis generating study, but an independent validation
analysis confirming the results of Hogewoning et al. [18]. The
comparable significantly increased regression rate among consis-
tent condom users (hazard ratio 4.4) underlines that consistent
condom use has a positive effect on regression of CIN2-3 lesions.
Three hypothetical explanations for the increased regression
rate by consistent condom use can be discussed. First, the
reduction of repetitively exposure of the cervical mucosa to
HPV may strengthen the local immune system defence against the
HPV infection and promote CIN regression. Secondly, the
immunosuppressive effect of semen mediated by prostaglandins
may play a role [22,23]. This effect seems to be biologically
meaningful for reproduction, but can diminish the patients
defence against HPV in CIN2-3 lesions and potentially inhibit
CIN regression [24]. A third intriguing hypothesis to explain the
higher regression rate of consistent condom users may be that the
latex of the condoms stimulates the general cellular immune
response, which might be beneficial in the clearance of HPV.
Condom Use and CIN2-3 Regression
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Condom use as contraception was rather infrequent in the study
population, and only 12% used condoms consistently. The current
results, indicating that consistent condom use considerably
increases the probability to regress and consequently reduces the
risk for cone excision, could motivate a higher proportion of
women to use this contraception type for a limited period of time.
Motivation meetings including the patients` partners may also be
important to increase compliance rate according consistent
condom use.
The non-hormonal contraception group had a significantly
higher regression rate than the hormonal contraception group.
However, this difference was not longer significant after correcting
for condom use. After excluding condom users, there was still no
significant difference in regression rates between hormonal versus
non-hormonal contraception users.
Previous studies have shown a decreasing regression rate with
increasing CIN grade [4,25]. In the current study we found the
same trend, but the difference was not significant. The current
study was underpowered to detect significant differences in CIN
subgroups. Based on the observed 11% difference in regression
rates, 654 first time onset CIN2-3 patients are needed to perform
a study with adequate statistical power.
Smoking is a risk factor for CIN and invasive cancer
development, and has been reported to be associated with
decreased probability of regression [14,26]. We found a lower,
but not significant regression rate in smokers versus non-smokers
Table 1. Clinical characteristics of the study population according to regression or non-regression.
Regression (n = 38) Non-regression (n = 132) p-value
Median age, years (range) 30.3 (25.1–41.0) 31.2 (25.0–41.0) 0.67
Median interval biopsy–cone excision, days (range) 113 (84–154) 113 (84–171) 0.22
Sexual activity span, years (range) 13.0 (6.1–25.4) 13.6 (6.0–25.6) 0.47
Age at first birth, years (range) 24.0 (18–38) 24.0 (16–32) 0.48
Histology
CIN2 12 (31%) 27 (69%) 0.19
CIN3 26 (20%) 105 (80%)
Currently smoking
Yes 10 (18%) 45 (82%) 0.43
No 28 (24%) 87 (76%)
Number of lifetime sexual partners
1–4 8 (31%) 18 (69%) 0.31
$5 30 (21%) 114 (79%)
Number of lifetime sexual partners
1–9 20 (25%) 60 (75%) 0.47
$10 18 (20%) 72 (80%)
Age at first sexual intercourse, years
#15 5 (11%) 39 (89%) 0.04
.15 33 (26%) 33 (26%)
Parity
Nulliparous 16 (26%) 45 (74%) 0.44
Primi/multiparous 22 (20%) 87 (80%)
Parity
0–2 35 (24%) 113 (76%) 0.41
3–4 3 (14%) 19 (86%)
Contraception
Non-hormonal 26 (29%) 65 (71%) 0.04
Hormonal 12 (15%) 67 (85%)
Consistent condom use
Yes 11 (55%) 9 (45%) 0.001
No 27 (18%) 123 (82%)
Condom use
Consistent 11 (55%) 9 (45%) 0.03
Inconsistent 3 (19%) 13 (81%)
Condom use
Inconsistent 3 (19%) 13 (81%) 0.9
No 24 (18%) 110 (82%)
doi:10.1371/journal.pone.0045114.t001
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(18% versus 24%). Two other studies on 100 and 125 patients
came to the same conclusion [5,18]. However, again the current
study was probably underpowered to detect this difference, and
with an alpha of 0.05, and a power of 0.80, one would need at least
400 patients.
It has been hypothesised that taking diagnostic biopsies may
induce CIN regression by eliciting a local inflammatory response,
which might influence the natural history on CIN. Further
research concerning the biopsy-induced immune response is
warranted.
The strengths of the current study are the prospective nature,
the consecutive follow-up of all women with a first time onset
CIN2-3 and the histological definition of CIN for the diagnosis
and for CIN regression. Furthermore, two independent patholo-
gists set the diagnoses, including the immunohistochemical
biomarkers p16 and Ki67 as supporting analyses for CIN grading.
Stavanger University Hospital is the only hospital in the region,
making this a population-based study, which minimizes selection
biases. Moreover, the patients’ age and interval between punch
biopsies and cone excision was limited, which allows observing the
natural history of CIN in a defined age group and time aspect.
A limitation of the study was the relatively short observational
period between biopsy and cone excision as regression can take
from months to years [4,27,28]. However, a longer observational
period in the CIN2-3 patients would have been difficult to justify
at the start of the study, as a longer interval with the subset
histological diagnosis was regarded as to risky with respect to
progression to cancer by the Ethical committee. Further, the
sample size was rather moderate, which limits the separate
interpretation of regression in some of the subgroups (i.e. smoking,
CIN grade 2 or 3, CIN or cervical cancer in 1st or 2nd degree
relatives).
In conclusion, this prospective study shows that consistent
condom use over a median time period of 113 days increases the
regression rate from 18% to 55%, while non-consistent condom
use does not (19%). Based on the current data, consistent condom
use for a limited time with thorough follow-up seems a promising
intervention for younger women. It remains to be assessed if even
higher regression rates can be achieved by longer consistent
condom use exceeding the current study period.
Acknowledgments
The laboratory work of Bianca van Diermen Hidle is greatly acknowl-
edged. The assistance of the nurses at the gynecology outpatient clinic was
very much appreciated.
Author Contributions
Conceived and designed the experiments: JPAB ACM EAMJ AJK KIL BF
EG AM. Performed the experiments: ACM EG ITØ. Analyzed the data:
ACM EAMJ JPAB FV. Contributed reagents/materials/analysis tools:
ACM EG BF KIL ITØ. Wrote the paper: ACM JPAB EAMJ AM FV.
References
1. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, et al. (2004) Against
which human papillomavirus types shall we vaccinate and screen? The
international perspective. Int J Cancer 111: 278–285.
2. Baak JP, Kruse AJ, Robboy SJ, Janssen EA, van Diermen B, et al. (2006)
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with
molecular biomarkers. J Clin Pathol 59: 1017–1028.
3. Nasiell K, Nasiell M, Vaclavinkova V (1983) Behavior of moderate cervical
dysplasia during long-term follow-up. Obstet Gynecol 61: 609–614.
4. Ostor AG (1993) Natural history of cervical intraepithelial neoplasia: a critical
review. Int J Gynecol Pathol 12: 186–192.
5. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, et al. (2005)
Spontaneous regression of high-grade cervical dysplasia: effects of human
papillomavirus type and HLA phenotype. Clin Cancer Res 11: 4717–4723.
6. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, et al. (2008) Natural
history of cervical neoplasia and risk of invasive cancer in women with cervical
intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9: 425–
434.
7. Hagen B, Skjeldestad FE, Bratt H, Tingulstad S, Lie AK (1998) CO2 laser
conization for cervical intraepithelial neoplasia grade II-III: complications and
efficacy. Acta Obstet Gynecol Scand 77: 558–563.
8. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, et al.
(2006) Obstetric outcomes after conservative treatment for intraepithelial or
early invasive cervical lesions: systematic review and meta-analysis. Lancet 367:
489–498.
9. Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE (2008)
Pregnancy outcome in women before and after cervical conisation: population
based cohort study. BMJ 337: a1343.
10. Steen R, Johansen BK, Skare G, Haldorsen T, Eriksen T, et al. (2009)
A˚rsrapporten 2008. The Cancer Registry.
11. Collins S, Rollason TP, Young LS, Woodman CB (2010) Cigarette smoking is
an independent risk factor for cervical intraepithelial neoplasia in young women:
a longitudinal study. Eur J Cancer 46: 405–411.
12. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A (2011)
Smoking habit, immune suppression, oral contraceptive use, and hormone
replacement therapy use and cervical carcinogenesis: a review of the literature.
Gynecol Endocrinol 27: 1–8.
13. Syrjanen K, Vayrynen M, Castren O, Yliskoski M, Mantyjarvi R, et al. (1984)
Sexual behaviour of women with human papillomavirus (HPV) lesions of the
uterine cervix. Br J Vener Dis 60: 243–248.
14. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history of
cervicovaginal papillomavirus infection in young women. N Engl J Med 338:
423–428.
15. International Collaboration of Epidemiological Studies of Cervical Cancer
(2009) Cervical carcinoma and sexual behavior: collaborative reanalysis of
individual data on 15,461 women with cervical carcinoma and 29,164 women
without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol
Biomarkers Prev 18: 1060–1069.
16. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, et al. (2002) Role of
parity and human papillomavirus in cervical cancer: the IARC multicentric
case-control study. Lancet 359: 1093–1101.
17. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, et al. (2003)
Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet
361: 1159–1167.
18. Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, et al.
(2003) Condom use promotes regression of cervical intraepithelial neoplasia and
clearance of human papillomavirus: a randomized clinical trial. Int J Cancer
107: 811–816.
19. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Snijders PJ, et al.
(2003) Condom use promotes regression of human papillomavirus-associated
penile lesions in male sexual partners of women with cervical intraepithelial
neoplasia. Int J Cancer 107: 804–810.
20. Munk AC, Kruse AJ, van Diermen B, Janssen EA, Skaland I, et al. (2007)
Cervical intraepithelial neoplasia grade 3 lesions can regress. APMIS 115: 1409–
1414.
21. Discacciati MG, de Souza CA, d’Otavianno MG, Angelo-Andrade LA, Westin
MC, et al. (2011) Outcome of expectant management of cervical intraepithelial
neoplasia grade 2 in women followed for 12 months. Eur J Obstet Gynecol
Reprod Biol 155: 204–208.
22. Kelly RW (1995) Immunosuppressive mechanisms in semen: implications for
contraception. Hum Reprod 10: 1686–1693.
23. Kelly RW (1997) Prostaglandins in primate semen: biasing the immune system
to benefit spermatozoa and virus? Prostaglandins Leukot Essent Fatty Acids 57:
113–118.
24. Wang X, Zhuang J, Wu K, Xu R, Li M, et al. (2010) Human semen: the
biological basis of sexual behaviour to promote human papillomavirus infection
and cervical cancer. Med Hypotheses 74: 1015–1016.
25. Kataja V, Syrjanen K, Mantyjarvi R, Vayrynen M, Syrjanen S, et al. (1989)
Prospective follow-up of cervical HPV infections: life table analysis of
histopathological, cytological and colposcopic data. Eur J Epidemiol 5: 1–7.
26. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, et al. (2010) Tobacco
smoking and regression of low-grade cervical abnormalities. Cancer Sci 101:
2065–2073.
27. van Oortmarssen GJ, Habbema JD (1991) Epidemiological evidence for age-
dependent regression of pre-invasive cervical cancer. Br J Cancer 64: 559–565.
28. Holowaty P, Miller AB, Rohan T, To T (1999) Natural history of dysplasia of
the uterine cervix. J Natl Cancer Inst 91: 252–258.
Condom Use and CIN2-3 Regression
PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45114
